|
|
|
|
|
Over the last decade, EBRP has made remarkable strides, including helping to accelerate the first two EB treatments FDA approved in 2023.
Since our founding, we have funded 140 research projects laser-focused on bringing life-saving therapies and cures to the EB community. Our work has transformed the clinical trial landscape from just 2 clinical trials in EB to over 40 today, an almost 20x increase. 
|
|
"Adapting the iPS Cell-Based Therapy for RDEB to an Automated Platform to Facilitate Clinical Translation" |
"Suppressing the Itch of Dystrophic Epidermolysis Bullosa" |
"Development of a Novel Ophthalmic Solution to Treat Ocular Manifestations of RDEB" |
